Susquehanna International Group
BPMC

Susquehanna International Group’s Blueprint Medicines BPMC Stock Holding History

Susquehanna International Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,400
Closed -$12.2M – 12437
2025
Q2 		$12.2M Sell
95,400
-154,200
-62% -$16M ﹤0.01% 2585
2025
Q1 		$22.1M Buy
249,600
+78,300
+46% +$7.64M ﹤0.01% 1659
2024
Q4 		$14.9M Buy
171,300
+8,600
+5% +$788K ﹤0.01% 2172
2024
Q3 		$15M Sell
162,700
-49,300
-23% -$4.9M ﹤0.01% 2121
2024
Q2 		$22.8M Buy
212,000
+51,200
+32% +$5.12M ﹤0.01% 1590
2024
Q1 		$15.3M Buy
160,800
+64,100
+66% +$5.5M ﹤0.01% 2089
2023
Q4 		$8.92M Buy
96,700
+52,000
+116% +$3.37M ﹤0.01% 2789
2023
Q3 		$2.24M Sell
44,700
-21,900
-33% -$1.17M ﹤0.01% 4900
2023
Q2 		$4.21M Sell
66,600
-25,200
-27% -$1.37M ﹤0.01% 3804
2023
Q1 		$4.13M Buy
91,800
+47,300
+106% +$2.13M ﹤0.01% 3736
2022
Q4 		$1.95M Sell
44,500
-80,200
-64% -$3.85M ﹤0.01% 4746
2022
Q3 		$8.22M Buy
124,700
+20,400
+20% +$1.31M ﹤0.01% 2440
2022
Q2 		$5.27M Buy
104,300
+54,900
+111% +$3.22M ﹤0.01% 3105
2022
Q1 		$3.16M Buy
49,400
+25,500
+107% +$1.83M ﹤0.01% 4530
2021
Q4 		$2.56M Sell
23,900
-12,300
-34% -$1.29M ﹤0.01% 4949
2021
Q3 		$3.72M Hold
36,200
– – ﹤0.01% 4503
2021
Q2 		$3.18M Buy
36,200
+1,100
+3% +$101K ﹤0.01% 4890
2021
Q1 		$3.41M Buy
35,100
+10,200
+41% +$1.02M ﹤0.01% 4679
2020
Q4 		$2.79M Sell
24,900
-79,900
-76% -$8.42M ﹤0.01% 4422
2020
Q3 		$9.71M Buy
104,800
+25,200
+32% +$1.94M ﹤0.01% 2218
2020
Q2 		$6.21M Sell
79,600
-11,800
-13% -$798K ﹤0.01% 2713
2020
Q1 		$5.34M Buy
91,400
+14,500
+19% +$933K ﹤0.01% 2493
2019
Q4 		$6.16M Sell
76,900
-451,700
-85% -$33.8M ﹤0.01% 2698
2019
Q3 		$38.8M Buy
528,600
+169,100
+47% +$14.6M 0.01% 885
2019
Q2 		$33.9M Buy
359,500
+290,200
+419% +$24M 0.01% 921
2019
Q1 		$5.55M Buy
69,300
+4,000
+6% +$296K ﹤0.01% 2337
2018
Q4 		$3.52M Buy
65,300
+21,900
+50% +$1.33M ﹤0.01% 2707
2018
Q3 		$3.39M Sell
43,400
-77,400
-64% -$5.38M ﹤0.01% 3189
2018
Q2 		$7.67M Buy
120,800
+75,600
+167% +$6.02M ﹤0.01% 2213
2018
Q1 		$4.14M Sell
45,200
-119,100
-72% -$10.3M ﹤0.01% 2778
2017
Q4 		$12.4M Buy
164,300
+144,400
+726% +$10.2M ﹤0.01% 1653
2017
Q3 		$1.39M Buy
19,900
+13,300
+202% +$711K ﹤0.01% 4630
2017
Q2 		$334K Sell
6,600
-10,000
-60% -$425K ﹤0.01% 7380
2017
Q1 		$664K Buy
16,600
+4,400
+36% +$158K ﹤0.01% 5962
2016
Q4 		$342K Buy
12,200
+3,900
+47% +$118K ﹤0.01% 7726
2016
Q3 		$247K Buy
+8,300
New +$206K ﹤0.01% 7238
2016
Q1 		– Sell
-10,700
Closed -$282K – 9010
2015
Q4 		$282K Buy
+10,700
New +$241K ﹤0.01% 7804

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's BPMC Position: Q3 2025 in Review

Susquehanna International Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 184,115 shares — an estimated $23.6M sold.

Susquehanna International Group first reported a position in BPMC in Q4 2017 and held it in 28 quarters. The position peaked at $36.5M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Susquehanna International Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 184,115 Blueprint Medicines shares in Q3 2025, an estimated $23.6M.
  • Susquehanna International Group first reported a position in Blueprint Medicines in Q4 2017 and held it in 28 quarters.
  • Susquehanna International Group's Blueprint Medicines position peaked at $36.5M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.